Humoral Immunity after mRNA Omicron JN.1 Vaccination

Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V. Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M. N. Behrens, Alexandra Dopfer-Jablonka
{"title":"Humoral Immunity after mRNA Omicron JN.1 Vaccination","authors":"Christine Happle, Markus Hoffmann, Amy Kempf, Inga Nehlmeier, Metodi V. Stankov, Noemi Calderon Hampel, Torsten Witte, Stefan Pöhlmann, Georg M. N. Behrens, Alexandra Dopfer-Jablonka","doi":"10.1101/2024.09.04.24313057","DOIUrl":null,"url":null,"abstract":"In late June 2024, the European Medicines Agency (EMA) recommended market authorization for a monovalent COVID-19 mRNA-vaccine based on JN.1 spike. We assessed immune responses in n=42 health-care workers (median age 47 years, interquartile range, IQR 19·5 years, 48% male), who in August 2024 were vaccinated with 30 μg of the updated mRNA omicron JN.1 vaccine (bretovameran, BioNTech/Pfizer, Mainz, Germany). Humoral immune responses were analyzed directly prior to and 13 days after vaccination.","PeriodicalId":501509,"journal":{"name":"medRxiv - Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Infectious Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.04.24313057","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

In late June 2024, the European Medicines Agency (EMA) recommended market authorization for a monovalent COVID-19 mRNA-vaccine based on JN.1 spike. We assessed immune responses in n=42 health-care workers (median age 47 years, interquartile range, IQR 19·5 years, 48% male), who in August 2024 were vaccinated with 30 μg of the updated mRNA omicron JN.1 vaccine (bretovameran, BioNTech/Pfizer, Mainz, Germany). Humoral immune responses were analyzed directly prior to and 13 days after vaccination.
接种 mRNA Omicron JN.1 疫苗后的体液免疫
2024 年 6 月底,欧洲药品管理局(EMA)建议批准基于 JN.1 穗状病毒的单价 COVID-19 mRNA 疫苗上市。我们评估了 n=42 名医护人员(中位年龄 47 岁,四分位数间距 19-5 岁,48% 为男性)的免疫反应,他们于 2024 年 8 月接种了 30 μg 更新的 mRNA omicron JN.1 疫苗(bretovameran,BioNTech/辉瑞,德国美因茨)。接种前和接种后 13 天直接分析体液免疫反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信